Aman Bio

Michael G. Aman, Ph.D.

Professor of Psychology & Psychiatry
175C McCampbell Hall
aman.1@osu.edu
(614) 688-4196

Group Email: psychmed@osu.edu

Michael G. Aman, Ph.D.

Dr. Michael Aman is an experimental psychologist, collaborator, and principal investigator on a number of pharmacological and behavioral studies. He is a professor of Psychology and Psychiatry, and he is coordinator of the O.S.U. doctoral program in Intellectual and Developmental Disabilities. He has been extensively involved in development of standardized rating instruments, including the Aberrant Behavior Checklist and the Nisonger Child Behavior Rating Form. Some of his publications appear below.

Positions

July 1994-Present
Professor of Psychology and Psychiatry, O.S.U. (the Nisonger Center).

Aug. 1987‑July 1994
Associate Professor of Psychology and Psychiatry, O.S.U. (the Nisonger Center).

July 1982‑ July 1987
New Zealand Medical Research Council, Senior Research Fellow, Department of Psychiatry, University of Auckland.

Current Editorial Boards

  • American Journal on Mental Retardation, 1993-present.
  • Clinical Medicine: Pediatrics, 2007-present.
  • Clinical Medicine: Psychiatry, 2007-present.
  • Clinical Therapeutics, 2002-present.
  • Journal of Child and Adolescent Psychopharmacology, 1990-present.
  • Journal of Intellectual and Developmental Disability
    Research in Developmental Disabilities, 1980-present.
  • Associate Editor, Journal of Mental Health in Intellectual Disabilities, 2007-present.
  • Ad hoc reviewing for many other journals.

Honors

  • 1982‑1987: New Zealand Medical Research Council, Senior Research Fellow
  • 2003: Academy on Mental Retardation, Career Scientist Award.
  • 2007: Member, Scientific Advisory Board, General Clinical Research Center, Ohio State University, June 2004 to present.

Selected Peer Reviewed Publications (of 150)

Aman, M.G., Singh, N.N., Stewart, A.W., et al. (1985). The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89, 485-491.

Aman, M.G., Singh, N.N., Stewart, A.W., & Field, C. (1985). Psychometric characteristics of the Aberrant Behavior Checklist. American Journal of Mental Deficiency, 89, 492-502.

Aman, M.G., Singh, & Turbott, S.H. (1987). Reliability of the Aberrant Behavior Checklist and the effect of variations in instructions. American Journal of Mental Deficiency, 92, 237‑240.

Aman, M.G., et al. (1989). Haloperidol treatment with chronically medicated residents: Dose effects on clinical behavior and reinforcement contingencies. American Journal on Mental Retardation, 93, 452‑460.

Aman, M.G. (1991). Assessing psychopathology and behavior problems in persons with mental retardation: A review of available instruments. (DHHS Publication No. [ADM] 91‑1712.) Rockville, MD: U.S. Department of Health and Human Services.

Aman, M.G., Marks, R.E., et al. (1991). Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 246‑256.

Aman, M.G., et al. (1995). The Aberrant Behavior Checklist-Community: Factor validity and effect of subject variables for adults in group homes. American Journal on Mental Retardation, 100, 283-292.

Aman, M.G., Tassé, M.J.,Rojahn, J. & Hammer, D. (1996). The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Research in Developmental Disabilities, 17, 41-57.

Aman, M.G., Kern, R.A., Osborne, P. et al. (1997). Fenfluramine and methylphenidate in children with mental retardation and borderline IQ: Clinical effects. American Journal on Mental Retardation, 101, 521-534.

Aman, M.G. Madrid, A. (1999). Atypical antipsychotics in persons with developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 253-263.

Werry, J.S., Aman, M.G. (1999). Practitioner’s guide to psychoactive drugs for children and adolescents (2nd ed.). New York: Plenum Press.
Aman, M.G., Armstrong, S., Buican, B., & Sillick, T. (2002). Four-year follow-up of children with low intelligence and ADHD: A replication. Research in Developmental Disabilities, 23, 119-134.

Aman, M.G., et al. (2002). Risperidone treatment of children with disruptive behavior disorders and sub-average IQ: A double-blind, placebo-controlled study. American Journal of Psychiatry, 159, 1337-1346.

RUPP Autism Network (including Aman, M.G., PI at O.S.U.) (2002). A double-blind, placebo-controlled trial of risperidone in children with autistic disorder. New England Journal of Medicine, 347 , 314-321.

Aman, M.G., Buican, B., & Arnold, L.E. (1993). Methylphenidate treatment in children with low IQ and ADHD: Analysis of three aggregated studies. Journal of Child and Adolescent Psychopharmacology, 13, 27-38.

Aman, M.G., Langworthy, K.S., & Collier-Crespin, A. (2003). Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. Journal of Autism and Developmental Disorders, 33, 527-534.

Aman, M.G., Novotny, S., Samango-Sprouse, C., Lecavalier, L., Leonard, E., Gadow, K., King, B., Pearson, D.A., et al.(2004).Outcome measures for clinical drug trials in autism. CNS Spectrums, 9, 36-47.

Aman, M.G. (2005). Treatment planning for patients with autism spectrum disorders. Journal of Clinical Psychiatry, 66(suppl. 10), 38-45.

Aman, M.G., Arnold, L.E., McDougle, C.J. , Vitiello, B., Scahill, L., Davies, M., McCracken, J.T., Tierney, E., Nash, P.L., Posey, D.J. Chuang, S., Martin, A., Shah, B., Gonzalez, N.M, Swiezy, N.B., Ritz, L., Koenig, K., McGough, J., Ghuman, J.K., & Lindsay, R.L. (2005). Acute and long-term safety and tolerability of risperidone in children with autism. Journal Child Adolescent Psychopharmacology 15, 869-884.

Aman, M.G., Lam, K.S.L., et al. (2005). Medication patterns in patients with autism: Temporal, regional, and demographic influences. Journal of Child and Adolescent Psychopharmacology, 15, 116-126.

RUPP Autism Network. (2005). Risperidone treatment of autistic disorder: Longer term benefits and blinded discontinuation after six months. American Journal of Psychiatry, 162, 1361-1369.

Research Units on Pediatric Psychopharmacology Autism Network (incl. M.G. Aman, PI at OSU). (2005). A randomized, double-blind, placebo-controlled, crossover trial of methylphenidate in children with hyperactivity associated with pervasive developmental disorders. Arch. Gen. Psychiatry, 62, 1266-1274.

Aman, MG, Vinks, AA, Remmerie, B, Mannaert, E., et al. (2007). Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Clinical Therapeutics, 29, 1476-1486.

Lam, K.S.L. & Aman, M.G. (2007). The Repetitive Behavior ScaleCRevised: Independent validation in individuals with autism spectrum disorders. Journal of Autism and Developmental Disorders, 37, 855-866.

Aman, M.G., Leone, S., Lecavalier, L., Park, L., et al. (2008). The Nisonger Child Behavior Rating Form—Typical IQ Version, for children with typical IQ. International Clinical Psychopharmacology, 23, 232-242.